drugset / Trial / NCT05433584

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

NCT05433584

Phase 4 Active not recruiting 780 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

Timeline

Start
2022-08-01
Primary completion
2025-10-21
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 15 mg Subcutaneous